Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: email@example.com. Type 508 Accommodation in the subject line of e-mail.
Yellow Fever Vaccine Recommendations of the Immunization Practices Advisory Committee (ACIP)
These revised Immunization Practices Advisory Committee (ACIP) recommendations on yellow fever vaccine update previous recommendations (MMWR 1984;32:679-88). Changes have been made to clarify 1) the risks of acquiring yellow fever associated with travel to endemic areas, 2) the precautions necessary for vaccination of special groups (immunosuppressed individuals, infants, pregnant women), and 3) simultaneous administration of cholera vaccine and other vaccines. INTRODUCTION
Yellow fever presently occurs only in Africa and South America. Two forms of yellow fever--urban and jungle--are epidemiologically distinguishable. Clinically and etiologically they are identical (1,2).
Urban yellow fever is an epidemic viral disease of humans transmitted from infected to susceptible persons by Aedes aegypti mosquitoes, which breed in domestic and peridomestic containers (e.g., water jars, barrels, drums, tires, tin cans) and thus in close association with humans. In areas where Ae. aegypti has been eliminated or suppressed, urban yellow fever has disappeared. In the early 1900s, eradication of Ae. aegypti in a number of countries, notably Panama, Brazil, Ecuador, Peru, Bolivia, Paraguay, Uruguay, and Argentina, led to the disappearance of urban yellow fever. The last documented Ae. aegypti-borne yellow fever epidemic in the western hemisphere occurred in Trinidad in 1954. Ae. aegypti is suspected to have played a role in transmission in outbreaks occurring in Bolivia in 1989 and 1990, but that role was not proven. However, periodic reinfestations of some countries have occurred in recent years (Brazil, Bolivia, Ecuador, Panama). Other countries remain infested, including areas of Venezuela, Colombia, and the Guyanas, which include enzootic areas for jungle yellow fever. In West Africa, Ae. aegypti-transmitted epidemics continue to occur and involve human populations both in towns and in rural villages (3).
Jungle yellow fever is an enzootic viral disease transmitted among nonhuman primate hosts by various mosquito vectors. It is currently observed only in forest-savannah zones of tropical Africa and in forested areas of South America but occasionally extends into parts of Central America and the island of Trinidad. In South America, approximately 100-300 cases are reported annually, mainly among men with occupational exposures in forested areas; however, the disease is believed to be greatly underreported. In Africa, epidemics involving tree-hole-breeding mosquito vectors affect tens of thousands of persons at intervals of a few years, but few cases are officially reported. Sometimes the disease is not detected in an area for years but then will reappear. Delineation of affected areas depends on surveillance of animal reservoirs and vectors, accurate diagnosis, and prompt reporting of all human cases. The jungle yellow fever cycle may be active but unrecognized in forested areas of countries within the yellow fever endemic zone (Figure 1).
Urban yellow fever can be prevented by eradicating Ae. aegypti mosquitoes or by suppressing their numbers to the point that they no longer perpetuate infection. Jungle yellow fever can most effectively be prevented by vaccination of human populations at risk of exposure. YELLOW FEVER VACCINE
Yellow fever vaccine is a live, attenuated virus preparation made from the 17D yellow fever virus strain (4). The 17D vaccine is safe and effective (5). The virus is grown in chick embryos inoculated with a seed virus of a fixed-passage level. The vaccine is a freeze-dried supernate of centrifuged embryo homogenate, packaged in 1-dose and 5-dose vials for domestic use.
Vaccine should be stored at temperatures between 5 C (41 F) and -30 C (-22 F)--preferably frozen, below 0 C (32 F)--until it is reconstituted by the addition of diluent sterile, physiologic saline supplied by the manufacturer. Multiple-dose vials of reconstituted vaccine should be held at 5 C-10 C (41 F-50 F); unused vaccine should be discarded within 1 hour after reconstitution. VACCINE USAGE
to or living in areas of South America and Africa where yellow fever infection is officially reported should be vaccinated. These areas are listed in the "Bi-Weekly Summary of Countries with Areas Infected with Quarantinable Diseases," available in state and local health departments. Information on known or probably infected areas is also available from the World Health Organization (WHO) and Pan American Health Organization offices or the Division of Vector-Borne Infectious Diseases, Center for Infectious Diseases, CDC, Fort Collins, Colorado, telephone (303) 221-6400. Vaccination is also recommended for travel outside the urban areas of countries that do not officially report the disease but that lie in the yellow fever endemic zone (shaded area, Figure 1). The actual areas of yellow fever virus activity far exceed the infected zones officially reported; in recent years, fatal cases of yellow fever have occurred among unvaccinated tourists visiting rural areas within the yellow fever endemic zone (6).
2. Infants less than 9 months of age and pregnant women should be considered for vaccination if traveling to areas experiencing ongoing epidemic yellow fever when travel cannot be postponed and a high level of prevention against mosquito exposure is not feasible. However, in no instance should infants less than 4 months of age receive yellow fever vaccine because of the risk of encephalitis (see Precautions and Contraindications).
3. Laboratory personnel who might be exposed to virulent yellow fever virus by direct or indirect contact or by aerosols should also be vaccinated. B. Vaccination for international travel.
For purposes of international travel, yellow fever vaccines produced by different manufacturers worldwide must be approved by WHO and administered at an approved Yellow Fever Vaccination Center. State and territorial health departments have the authority to designate nonfederal vaccination centers; these can be identified by contacting state or local health departments. Vaccinees should receive an International Certificate of Vaccination completed, signed, and validated with the center's stamp where the vaccine is given. Vaccination for international travel may be required under circumstances other than those specified herein. Some countries in Africa require evidence of vaccination from all entering travelers. Some countries may waive the requirements for travelers coming from noninfected areas and staying less than 2 weeks. Because requirements may change, all travelers should seek current information from health departments. Travel agencies, international airlines, and/or shipping lines should also have up-to-date information. Some countries require an individual, even if only in transit, to have a valid International Certificate of Vaccination if s/he has been in countries either known or thought to harbor yellow fever virus. Such requirements may be strictly enforced, particularly for persons traveling from Africa or South America to Asia. Travelers should consult Health Information for International Travel 1989 (7) to determine requirements and regulations for vaccination. C. Primary vaccination.
For persons of all ages, a single subcutaneous injection of 0.5 ml of reconstituted vaccine is used. D. Booster doses.
The International Health Regulations require revaccination at intervals of 10 years. Revaccination boosts antibody titer; however, evidence from several studies (8-10) suggests that yellow fever vaccine immunity persists for at least 30-35 years and probably for life. REACTIONS
Reactions to 17D yellow fever vaccine are generally mild. After vaccination, 2%-5% of vaccinees have mild headaches, myalgia, low-grade fevers, or other minor symptoms for 5-10 days. Fewer than 0.2% of the vaccinees curtail regular activities. Immediate hypersensitivity reactions, characterized by rash, urticaria, and/or asthma, are uncommon (incidence less than 1/1,000,000) and occur principally among persons with histories of egg allergy. Although greater than 34 million doses of vaccine have been distributed, only two cases of encephalitis temporally associated with vaccinations have been reported in the United States; in one fatal case, 17D virus was isolated from the brain. PRECAUTIONS AND CONTRAINDICATIONS
Determination of whether to administer yellow fever vaccine and other immunobiologics simultaneously should be made on the basis of convenience to the traveler in completing the desired vaccinations before travel and on information regarding possible interference. The following will help guide these decisions.
Studies have shown that the serologic response to yellow fever vaccine is not inhibited by the administration of certain other vaccines concurrently or at various intervals of a few days to 1 month. Measles and yellow fever vaccines have been administered in combination with full efficacy of each of the components; Bacillus Calmette Guerin (BCG) and yellow fever vaccines have been administered simultaneously without interference. Additionally, severity of reactions to vaccination has not been amplified by the concurrent administration of yellow fever and other live virus vaccines (11). If live virus vaccines are not given concurrently, 4 weeks should elapse between sequential vaccinations.
Some data have indicated that persons given yellow fever and cholera vaccines simultaneously or 1-3 weeks apart had lower than normal antibody responses to both vaccines (12,13). Unless there are time constraints, cholera and yellow fever vaccines should be administered at a minimal interval of 3 weeks. If the vaccines cannot be administered at least 3 weeks apart, the vaccines can be given simultaneously or at any time within the 3-week interval.
Hepatitis B and yellow fever vaccine may be given concurrently (14). No data exist on possible interference between yellow fever and typhoid, paratyphoid, typhus, plague, rabies, or Japanese encephalitis vaccines.
In a prospective study of persons given yellow fever vaccine and 5 cc of commercially available immune globulin, no alteration of the immunologic response to yellow fever vaccine was detected when compared with controls (15). Although chloroquine inhibits replication of yellow fever virus in vitro, it does not adversely affect antibody responses to yellow fever vaccine in humans receiving antimalaria prophylaxis (16).
Third report WHO tech rep, ser no. 4791, 1971.
3. Nasidi A, Monath TP, DeCock K, et al. Urban yellow fever epidemic in western Nigeria, 1987. Trans R Soc Trop Med Hyg 1989;84:401-6.
4. Smithburn KC, Durieux C, Koerber R, et al. Yellow fever vaccination. WHO monograph series no. 30. Geneva, 1956.
5. Wisseman CL Jr, Sweet BH. Immunological studies with group B arthropod-borne viruses. III. Response of human subjects to revaccination with 17D strain yellow fever vaccine. Am J Trop Med Hyg 1962;11:570-5.
6. Rodhain F, Hannoun C, Jousset FX, Ravisse P. Isolement du virus de la fievre jaune a Paris a partir de deux cas humains importes. Bull Soc Pathol Exot 1979;72:411-5.
7. CDC. Health information for international travel 1989. Atlanta: CDC, 1989; HHS publication no. (CDC)89-8280.
8. Groot H, Ribeiro RB. Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull WHO 1962;27:669-707.
9. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull WHO 1981;59:895-900. 10. Rosenzweig EC, Babione RW, Wisseman CL Jr. Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine. Am J Trop Med Hyg 1963;12:230-5. 11. Tauraso NM, Myers MG, Nau EV, et al. Effect of interval between inoculation of live smallpox and yellow fever vaccines on antigenicity in man. J Infect Dis 1972;126:363-71. 12. Felsenfeld O, Wolf RH, Gyr K, et al. Simultaneous vaccination against cholera and yellow fever. Lancet 1973;1:457-8. 13. Gateff C. Influence de la vaccination anticholoerique sur l'immunisation antiamarile associee. Bull Soc Pathol Exot 1973;66:258-66. 14. Yvonnet B, Coursaget P, Deubel V, et al. Simultaneous administration of hepatitis B and yellow fever vaccines. J Med Virol 1986;19:307-11. 15. Kaplan JE, Nelson DB, Schonberger LB, et al. The effect of immune globulin on trivalent oral polio and yellow fever vaccinations. Bull WHO 1984;62:585-90. 16. Tsai TF, Bolin RA, Lazuick JS, et al. Chloroquine does not adversely affect the antibody response to yellow fever vaccine. J Infect Dis 1986;154:726.
Disclaimer All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.**Questions or messages regarding errors in formatting should be addressed to firstname.lastname@example.org.
Page converted: 08/05/98
This page last reviewed 5/2/01